A Study of Tirzepatide Compared to Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT)

In by ECIR

A Study of Tirzepatide Compared to Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT)

  • This field is for validation purposes and should be left unchanged.
clinicaltrials.gov

Eligibility

Inclusion Criteria

T2DM
Confirmed atherosclerotic cardiovascular disease
HbA1c ≥7.0% to ≤10.5%
BMI ≥25 kg/m²

Exclusion Criteria

Had a major cardiovascular event within the last 60 days
T1DM
History of severe hypoglycemia and/or hypoglycemia unawareness within the last 6 months
Diabetic retinopathy; or diabetic maculopathy
Currently planning an artery revascularization
History of pancreatitis
History of ketoacidosis or hyperosmolar state/coma
Clinically significant gastric emptying abnormality or chronically take drugs that directly affect GI motility

Back to Current Studies